Source: JCO
Area: News
The Journal of Clinical Oncology has featured a study suggesting that younger patients who were treated with systemic carboplatin for retinoblatoma had a high incidence of ototoxicity.
Carboplatin-induced ototoxicity remains poorly defined but is of potential great consequence in children with retinoblastoma.
Researchers retrospectively assessed the incidence of ototoxicity and its risk factors in 60 children with retinoblastoma who were treated with carboplatin in combination with vincristine according to the St Jude RET-3 protocol (n = 23) or best clinical management (n = 37). (Read more...)
Uncategorized